Boehringer Ingelheim transfers commercialization rights for CT-155 to Click Therapeutics, backed by a $50 million investment, as Phase III CONVOKE data show improvements in negative symptoms of schizophrenia.
Written by: Mennatullah Mansour, PharmD
Reviewed By: Pharmacally Editorial Team
Boehringer Ingelheim and Click Therapeutics have signed a strategic agreement to advance commercialization of CT-155, an investigational prescription digital therapeutic designed to treat experiential negative symptoms of schizophrenia in adults. Under the deal, Boehringer will transfer full product responsibility, including commercial and marketing authorization rights, to Click Therapeutics, while making a $50 million Series D strategic investment and providing dedicated commercialization funding if the therapy receives U.S. regulatory clearance. CT-155 was co-developed by both companies.
Trial Results
Click Therapeutics will lead commercialization efforts, supported by Phase III data from the CONVOKE study (NCT05838625). The randomized, double-blind, controlled trial evaluated CT-155 as an adjunct to standard antipsychotic therapy compared with a digital control application in adults with schizophrenia experiencing negative symptoms. The study met its primary endpoint, demonstrating improvement in experiential negative symptoms measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP) at 16 weeks. CT-155 showed a Cohen’s D effect size of −0.36 (p=0.0003), corresponding to a 6.8-point reduction in symptom severity versus 4.2 points with the control, representing a 62% relative improvement.
Safety Results
Safety findings showed CT-155 was well tolerated. Adverse event rates were 8.3% with CT-155 compared with 13.4% in the digital control arm. No discontinuations were attributed to CT-155, and no serious adverse events related to treatment were reported in either group.
Real-World Study and Commercialization Strategy
Additional real-world-like data are being generated in the ENSPIRUS study (NCT06791122), which continues under Boehringer Ingelheim’s leadership. These data are expected to further inform engagement and clinical outcomes ahead of potential regulatory review.
Click Therapeutics’ CEO David Benshoof Klein said the agreement validates the company’s long-term digital therapeutics strategy and positions Click to lead development and commercialization of CT-155, which has received Breakthrough Device designation from U.S. regulators.
Boehringer Ingelheim’s therapeutic area head Jan Stefan Scheld emphasized that the collaboration has advanced a meaningful innovation for schizophrenia and that transferring responsibility enables Click to leverage its expertise to maximize patient impact.
CT-155 is an investigational prescription digital therapeutic designed to deliver interactive psychosocial interventions as an adjunct to antipsychotic treatment for individuals with schizophrenia experiencing negative symptoms. The therapy has not yet been authorized by any regulatory authority, and its safety and effectiveness remain under review.
Reference
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155, 09 April 2026, https://www.clicktherapeutics.com/news/click-therapeutics-and-boehringer-ingelheim-announce-series-d-investment-and-funding-to-advance-commercialization-of-ct-155
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155, 09 April 2026, https://www.boehringer-ingelheim.com/us/human-health/mental-health/schizophrenia/boehringer-and-click-announce-ct-155-funding-and-investment
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia (CONVOKE), ClinicalTrials.gov ID NCT05838625, https://clinicaltrials.gov/study/NCT05838625
About the Writer
Mennatullah Mansour is pursuing a PharmD and is based in Alexandria, Egypt. She is driven by a strong passion for continuous learning and professional development, with a focus on pharmaceutical care, patient health, and medication safety. Her interests include prescription processing, patient counseling, and interpreting clinical information. She brings a detail-oriented approach and a strong ability to translate medical knowledge into clear, accurate, and reliable content for healthcare audiences.
